Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: Immi who wrote (327)	9/14/1998 9:07:00 PM
From: Bharat H. Barai	Read Replies (2) \| Respond to of 410

I have heard from Cardiologist friends that J & J stents are hardly used now. 3 years ago J & J had 90% stent business. Medtronic introduced its stent but its stent has around 10% market in this area. Boston Scientific's stent has about 25% market in Europe with AVEI having about 40-45%. I heard from friends that AVEI is also coming with superb new peripheral stents. Last quarter AVEI made 91 cents, it is trading around 46. Medtronic has PE of 58, Guidant around 75. AVEI has PE of less than 25, based on last 2 quarters. So far, the Cardiologists here are not that impressed with NIR stent. I do not know if that will be National experience. Boston Scientific has big marketing muscle and connections. They can always start a price war. Since Medtronic and J & J have very small of stent share, they can buy out a company like AVEI at cheap price. Today, most angioplasties are followed by stent insertion. Same trend will happen world wide. I am giving you my educated speculation along with what I hear from my Cardiology friends. I would not advice any one where to put money. Make your own best judgement call. Bharat H. Barai MD